Know Labs

Know Labs to Present Clinical Research at the 2024 American Physiology Summit

Retrieved on: 
Friday, April 5, 2024
Health, Medical Devices, Diabetes, Biometrics, Health Technology, Clinical Trials, Biotechnology, CGM, MARD, Venous blood, Know Labs, Machine, APS, Mayo Clinic, Blood, American Physiological Society, FDA

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.
  • At the previous APS Summit, Know Labs presented results from its peer-reviewed, proof-of-principle study conducted in collaboration with Mayo Clinic, which assessed the accuracy of its RF dielectric sensor in identifying different analytes in vitro, proving a 100% accuracy rate in these tests.
  • Since then, Know Labs has published several clinical studies demonstrating the stability, repeatability, and accuracy of its non-invasive continuous blood glucose monitor.
  • Most recently, Know Labs announced interim results from its first clinical research protocol involving people with diabetes, using venous blood as a comparative reference and a machine learning model trained on data collected in a lab setting, which resulted in an overall MARD of 11.1%.

Know Labs’ Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study

Retrieved on: 
Wednesday, March 6, 2024
Technology, General Health, Health, Hardware, MARD, American Diabetes Association, Algorithm, CGM, Know Labs, Treatment, FDA, Blood, Dielectric spectroscopy, Data, Conference, Type 2 diabetes, ATTD, Type 2, Mayo Clinic, Clinical professor, Prediabetes, Clinical trial, RF, CWD, Medical device

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced interim results from its most recent clinical research study.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced interim results from its most recent clinical research study.
  • Dr. Virend K. Somers of the Mayo Clinic serves as an author and co-investigator on the clinical research protocol.
  • “Despite significant efforts in the development of non-invasive blood glucose monitoring solutions, delivering a highly accurate, economical, FDA-cleared non-invasive continuous glucose monitor (CGM) still remains to be seen.
  • On the held-out test dataset, blood glucose was estimated with a MARD of 11.1 ± 2.1% relative to venous blood.

Know Labs Announces the KnowU™, its Wearable Non-Invasive Continuous Glucose Monitor

Retrieved on: 
Tuesday, February 27, 2024
Consumer Electronics, Technology, Diabetes, Health, General Health, Wearables, Mobile Technology, Health Technology, Medical Devices, Research, Science, Hardware, Algorithm, Know Labs, CGM, Multimedia, FDA, Quality of life, Dielectric spectroscopy, Data collection, Prevalence, IP, Glucose, RF, Wrist, Forearm, Medical device

Know Labs , Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the KnowU™, its wearable non-invasive continuous glucose monitor (CGM).

Key Points: 
  • Know Labs , Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the KnowU™, its wearable non-invasive continuous glucose monitor (CGM).
  • The KnowU brings Know Labs closer to delivering the world’s first non-invasive blood glucose monitor to the global marketplace.
  • It records voltage values detected at each frequency to quantify, with trade-secret machine learning algorithms, real-time continuous blood glucose levels.
  • During 2024, Know Labs will deploy the KnowU in large-scale, external clinical trials while making refinements to the device and its algorithms.

Know Labs, Inc. Reports First Quarter FY2024 Results

Retrieved on: 
Wednesday, February 14, 2024
Technology, Health Technology, Health, Hardware, Research, Burn, Know Labs, Form 10-K, Earnings per share, Annual report, Security (finance), Bank statement, Cryptocurrency

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2023.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2023.
  • In Q1 FY 2024, Know Labs reported a net loss of $3.45 million dollars, compared to a net loss of $3.82 million dollars in Q1 FY 2023, a reduction in net loss of 9.8%.
  • Research and development expense for Q1 FY2024 was $1.48 million dollars as compared to $1.74 million dollars in Q1 FY 2023, a decrease of 14.7% year over year.
  • Net cash used in operations for Q1 FY 2024 was $3.39 million dollars compared with $2.92 million in Q1 FY 2023.

Know Labs, Inc. to Host Review of First Quarter Fiscal Year 2024 Results on February 14, 2024

Retrieved on: 
Wednesday, February 7, 2024
Wearables, Mobile Technology, Technology, Research, Medical Devices, Diabetes, Health Technology, Health, General Health, Science, Know Labs, Webcast, FDA

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its first quarter of the fiscal year 2024 ended on December 31, 2023, on February 14, 2024, beginning at 1:30 pm PT.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its first quarter of the fiscal year 2024 ended on December 31, 2023, on February 14, 2024, beginning at 1:30 pm PT.
  • Media and investors may access the live audio webcast at www.knowlabs.co/investors , beginning at 1:15 pm PT.
  • Questions to the Company’s management team can be submitted through the webcast portal during the meeting.
  • For more information on Know Labs and its progress in developing the first FDA-cleared non-invasive blood glucose monitoring device, visit www.knowlabs.co .

Know Labs to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Retrieved on: 
Tuesday, January 23, 2024
Research, Wearables, Mobile Technology, Technology, Medical Devices, Diabetes, Health Technology, Hardware, General Health, Health, Science, RF, Know Labs, Type 2 diabetes, International Fair, ATTD, Mayo Clinic, Clinical professor, Conference, Emerging technologies, Treatment, Prediabetes, Abstract, CWD, Medical device

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the company will be exhibiting at the International Fair of New Technologies in Diabetes at the 17 th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy on March 6-9, 2024.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the company will be exhibiting at the International Fair of New Technologies in Diabetes at the 17 th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy on March 6-9, 2024.
  • These results will be presented by Dr. Virend K. Somers of the Mayo Clinic, who serves as an author and co-investigator on Know Labs’ current clinical research protocol.
  • The protocol assesses the accuracy of the Know Labs radiofrequency (RF) sensor for non-invasive blood glucose measurement in participants with prediabetes and Type 2 diabetes using venous blood as comparative reference.
  • During the conference Know Labs will sponsor an invitation-only luncheon hosted by Children With Diabetes (CWD) where key thought leaders in the diabetes management field will discuss non-invasive glucose monitoring innovation.

Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
Tuesday, December 19, 2023
Diabetes, General Health, Health, Medical Devices, Know Labs, FDA, Depreciation, Burn, Earnings per share, Engineering, First generation, Sale, Research, Security (finance)

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the fourth quarter and fiscal year ended September 30, 2023.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the fourth quarter and fiscal year ended September 30, 2023.
  • Know Labs reported a net loss of $15.29 million dollars in FY2023, compared to a net loss of $20.07 million dollars in FY2022, a reduction in net loss of 23.8%.
  • Net cash used in operations for FY2023 was $10.35 million dollars compared with $6.92 million in the prior year.
  • Shareholder equity for the fiscal year 2023 was $3.74 million versus $9.86 million in fiscal year 2022.

Know Labs, Inc. to Host Review of Fiscal Year 2023 Results on December 19, 2023

Retrieved on: 
Monday, December 11, 2023
Health, Medical Devices, Diabetes, Technology, Wearables, Mobile Technology, Hardware, Biotechnology, Webcast, NYSE, Know Labs, FDA, Medical device

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its fiscal year ended on September 30, 2023, on December 19, 2023, beginning at 1:30 pm PT.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its fiscal year ended on September 30, 2023, on December 19, 2023, beginning at 1:30 pm PT.
  • Media and investors may access the live audio webcast at www.knowlabs.co/investors , beginning at 1:15 pm PT.
  • Questions to the Company’s management team can be submitted through the webcast portal during the meeting.
  • For more information on Know Labs and its progress in developing the first FDA-cleared non-invasive blood glucose monitoring device, visit www.knowlabs.co .

Know Labs Expands Board of Directors

Retrieved on: 
Wednesday, November 8, 2023
Science, Research, Hardware, General Health, Health, Consumer Electronics, Health Technology, Technology, Knowledge, American Diabetes Association, FDA, Patent, NYSE, Know Labs, Intellectual Ventures, Eli Lilly, Diabetes, IAM, Commercial, Head, Algorithm, Ellingson, IP, IBM, Diagnosis, Diabetes Care, Management, Pharmaceutical industry, Chemistry

Tim Londergan is the founder and CEO of Tangibly, Inc., developer of the globe’s pre-eminent trade secret management platform. Trade secrets are a key component of an IP asset base and include the company’s proprietary algorithms. Londergan has a Ph.D. in Chemistry and experience as a CEO and COO of technology companies, including Lumera, Wavefront Venture Labs and Operem. He spent several years as Head of Commercial Development at Intellectual Ventures--a six-billion-dollar global intellectual property fund. In that role he managed a project between Intellectual Ventures and Know Labs to enhance Know Labs’ IP portfolio. Recently, Londergan was named IAM 300 World’s Leading IP Strategist 2023.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of three new members to the Company’s Board of Directors.
  • Each new Director brings to the board extensive sector-relevant experience with deep knowledge of the science and the marketplace that is the focus of Know Labs.
  • In that role he managed a project between Intellectual Ventures and Know Labs to enhance Know Labs’ IP portfolio.
  • We are thrilled to have John Cronin, Larry Ellingson and Tim Londergan join our Board of Directors.”
    For more information on Know Labs, visit www.knowlabs.co .

Know Labs Presents at Third Annual Bernstein CGM Disruptors Conference, Details Significant Progress During the Past Year

Retrieved on: 
Tuesday, October 31, 2023
Technology, Research, Medical Devices, Diabetes, Health Technology, Hardware, Health, General Health, Science, Senior, CGM, FDA, Algorithm, Interest, Conference, Intellectual property, IP, NYSE, Know Labs, Medical device

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, will present at the third annual Bernstein CGM Disruptors Conference on Thursday, November 2, 2023.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, will present at the third annual Bernstein CGM Disruptors Conference on Thursday, November 2, 2023.
  • Presenters and institutional investors from across the globe will gather virtually to discuss the latest developments in continuous glucose monitoring (CGM) technology.
  • Pete Conley, Chief Financial Officer, and Senior Vice President of Intellectual Property (IP) at Know Labs, will provide an update on the company’s progress over the past year.
  • Interested parties can view Know Labs’ Bernstein CGM Disruptors Conference presentation on the company website .